- Home
- UDMY vs SNDX Comparison
UDMY vs SNDX Comparison
Compare UDMY & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UDMY
- SNDX
- Stock Information
- Founded
- UDMY 2009
- SNDX 2005
- Country
- UDMY United States
- SNDX United States
- Employees
- UDMY N/A
- SNDX N/A
- Industry
- UDMY Other Consumer Services
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- UDMY Real Estate
- SNDX Health Care
- Exchange
- UDMY Nasdaq
- SNDX Nasdaq
- Market Cap
- UDMY 1.1B
- SNDX 1.2B
- IPO Year
- UDMY 2021
- SNDX 2016
- Fundamental
- Price
- UDMY $9.71
- SNDX $16.04
- Analyst Decision
- UDMY Buy
- SNDX Strong Buy
- Analyst Count
- UDMY 9
- SNDX 10
- Target Price
- UDMY $11.11
- SNDX $36.20
- AVG Volume (30 Days)
- UDMY 1.3M
- SNDX 2.6M
- Earning Date
- UDMY 02-13-2025
- SNDX 03-04-2025
- Dividend Yield
- UDMY N/A
- SNDX N/A
- EPS Growth
- UDMY N/A
- SNDX N/A
- EPS
- UDMY N/A
- SNDX N/A
- Revenue
- UDMY $786,565,000.00
- SNDX $16,000,000.00
- Revenue This Year
- UDMY $3.57
- SNDX N/A
- Revenue Next Year
- UDMY $6.23
- SNDX N/A
- P/E Ratio
- UDMY N/A
- SNDX N/A
- Revenue Growth
- UDMY 7.91
- SNDX N/A
- 52 Week Low
- UDMY $6.67
- SNDX $12.06
- 52 Week High
- UDMY $11.65
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- UDMY 71.01
- SNDX 61.53
- Support Level
- UDMY $9.55
- SNDX $14.53
- Resistance Level
- UDMY $10.12
- SNDX $16.95
- Average True Range (ATR)
- UDMY 0.48
- SNDX 0.68
- MACD
- UDMY 0.28
- SNDX 0.12
- Stochastic Oscillator
- UDMY 75.59
- SNDX 63.67
About UDMY Udemy Inc.
Udemy Inc operates a marketplace platform at the center of a vibrant knowledge network. The Company operates under two operating and reportable segments Consumer and Enterprise, out of which the Enterprise segment derives the maximum revenue. Geographically, the company derives maximum revenue from North America. The company leverages data, technology, and insights for effective learning experiences. It helps individuals and organizations to possess effective skill acquisition and development with flexibility.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.